Immune Checkpoint Inhibitor

Cutaneous immune-related adverse events are highly dependent on melanoma subtype among immune checkpoint inhibitor therapy recipients, according to a study.

The addition of pembrolizumab to chemotherapy significantly extended survival among patients with advanced HER2-negative gastric or gastroesophageal junction cancer, according to results of the phase 3 KEYNOTE-859 study.

Cutaneous immune-related adverse events are associated with increased survival rates among immune checkpoint inhibitor recipients, particularly in patients with melanoma, according to a study.

High BMI appeared associated with increased risk for any-grade immune-related adverse events among a cohort of patients with advanced cancer undergoing treatment with immune checkpoint inhibitors.

Despite significantly extending survival for younger adults with advanced non-small cell lung cancer, immune checkpoint inhibitors have conferred only modest OS gains over time among patients aged older than 75 years, study results showed.

The addition of tumor treating fields to standard therapies significantly improved OS for certain patients with non-small cell lung cancer, according to the therapy’s manufacturer.

A triple-therapy combination extended OS compared with historical data among certain patients with advanced HPV-positive cancers, according to one of the agent’s manufacturers.

NASHVILLE, Tenn. — Patients who received immune checkpoint inhibitor therapy may have a greater risk for sarcoidosis, according to study results presented at CHEST Annual Meeting.

CHARLOTTE, N.C. — Type 3 autoimmune pancreatitis led to rapid pancreatic atrophy and functional endocrine failure despite steroid therapy or immune checkpoint inhibitor withdrawal, a researcher reported at ACG Annual Scientific Meeting.